HCS Pharma (HCS) STO Рейтинг, Обзоры и Информация

8 апр. 2022 г.

8 июн. 2022 г.

100% завершено

$209 720 767

28% цель завершено

734 022 685.00 USD

past

1 HCS

=

500 USD

Детали токена

Бегущая строка

HCS

Общее предложение

€ 7 million

Распределение токенов

European Digital Asset Exchange | https://www.edsx.ch/projects/hcs-pharma

Принимаемые валюты

BTC, CHF, EUR, USDT, DOLLAR

Минимальный вклад

500

TOKEN

Сведения о компании

Зарегистрированное название компании

HCS Pharma SAS

Зарегистрированная Страна

France

Компания основана

Jan 1, 2014

Бонусная структура

20% discount offered on final share price

дополнительные детали

Платформа

eos

категории

Платформа

О проекте HCS Pharma

HCS Pharma is a biotechnology company focused on in vitro R&D, specializing in high content (HCA) and high throughput (HCS) cell imaging screening. HCS Pharma sells products based on BIOMIMESYS® technology, and develops its own 3D cellular models in its proprietary BIOMIMESYS® extracellular matrix. BIOMIMESYS® 3D culture technology faithfully reproduces the natural microenvironment of cells in 3D, to ensure more predictive results from in vitro studies, to reduce the time and cost of R&D, and animal testing in pharmaceutical, nutraceutical and cosmetic companies. BIOMIMESYS® technology is also requested to be used in cell therapy and regenerative medicine, allowing HCS Pharma to become the leader in all biotechnology industries in the next 5 years.

Особенности

BIOMIMESYS® is a unique groundbreaking 3D cell culture technology which associates the behavior of a solid scaffold and of a hydrogel which provide a cell culture microenvironment reproducing all aspects of human tissues, including matrix architecture, cellular organization, cell-cell and cell-matrix interactions.

Depending on the organ, extracellular matrix components may vary as well their proportions, allowing a more or less dense and compact cellular environment (different Elastic Modulus, porosity).

BIOMIMESYS® matrices are made of Hyaluronic Acid (HA), the main glycosaminoglycan (GAG) of the ECM, collagens and adhesion proteins. Our patented manufacturing process allow preserving the natural properties of HA and therefore synthesizing proprietary Hydroscaffold™.

Техническая информация

HCS Pharma owns 2 cell culture labs and one automation lab equipped with a robotic platform named HAPIx, including 2 confocal HCS systems, ImageXpress micro confocal systems from Molecular Devices, and a ImageXpress micro XLS also from Molecular Devices and a chemical lab for BIOMIMESYS® production.

HCS Pharma Roadmap

18 months

- 6 months: Development of a sales force in the different countries in Europe.

- 1 year: New production line set up + Development of a technical support center in Taiwan + fundraising and/or IPO project.

- 18 months: Presence in the US.

10 Years

- In 3 years, from patient cells, we will be able to recreate small diseased organs to test molecules and find the most suitable therapy for personalized medicine.

- In 5 years, we will be able to find much more effective clinical drug candidates and therefore ultimately treat patients with cancer, Parkinson's disease, or Alzheimer's.

- In 10 years, we will be able to recreate complete organs for organ transplantation. And from animal cells, we will be able to recreate muscle and therefore cultured meat.

HCS Pharma Команда

Проверено 25%

Внимание. Существует риск того, что непроверенные члены на самом деле не являются членами команды

Nathalie Maubon

CEO

проверено

Elodie Vandenhaute

Project Manager

Zied Souguir

Biomaterial Department Manager

Gregory Maubon

Chief Development Officer and IA Project Leader

Советники

Проверено 100%

Mauro Andriotto

Advisor

проверено

HCS Pharma Интервью

Mauro Andriotto

As a team member, сan you tell us about your role in the ICO project?

I am the CEO of the European Digital Assets Exchange where HCS Pharma is listed on the primary market.

What do you think about idea?

It's an amazing company selected by the European Commission between the most 50 most disruptive biotech in Europe and there is the plan to list the company on the Frankfurt Stock Exchange by the end of the year.

Nathalie Maubon

As a team member, сan you tell us about your role in the ICO project?

We have decided to go public before the end of the year by a Reverse Take Over (RTO) with a pre-IPO fund-raising such as STO. This STO in pre-IPO will give the possibility to crypto investors to be onboarded.

What do you think about idea?

This STO coupled with the STO makes it possible to rally virtual currency investors with the traditional market.